Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $13.13

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received an average rating of “Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $13.13.

CMPX has been the topic of several recent research reports. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Leerink Partnrs upgraded shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Guggenheim reduced their price objective on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Finally, Wedbush restated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st.

Insider Transactions at Compass Therapeutics

In related news, insider Jonathan Anderman acquired 20,000 shares of the company’s stock in a transaction on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at approximately $32,340. This trade represents a 2,000.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Insiders own 29.80% of the company’s stock.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after acquiring an additional 12,917 shares during the last quarter. Strs Ohio bought a new stake in Compass Therapeutics in the first quarter worth $34,000. Independent Advisor Alliance purchased a new stake in Compass Therapeutics during the fourth quarter valued at $26,000. BNP Paribas Financial Markets bought a new position in Compass Therapeutics during the fourth quarter valued at $27,000. Finally, Mariner LLC purchased a new position in shares of Compass Therapeutics in the 4th quarter worth $30,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock opened at $2.40 on Monday. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The company’s fifty day simple moving average is $2.07 and its 200-day simple moving average is $2.21. The stock has a market capitalization of $331.87 million, a PE ratio of -5.85 and a beta of 1.41.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). As a group, research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.